Immucell Corp. (ICCC)
NASDAQ:ICCC
Want to see ICCC full AI Analyst Report?
ICCC Stock Chart & Stats
$6.24
-$0.45(-8.32%)
At close: 4:00 PM EST
$6.24
-$0.45(-8.32%)
Day’s Range― - ―
52-Week Range$4.52 - $8.99
Previous CloseN/A
Volume9.49K
Average Volume (3M)20.75K
Market Cap
$78.98M
Enterprise Value$88.28M
Total Cash (Recent Filing)$3.81M
Total Debt (Recent Filing)$13.19M
Price to Earnings (P/E)―
Beta-0.14
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding9,046,799
10 Day Avg. Volume22,482
30 Day Avg. Volume20,748
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)2.05
Price to Sales (P/S)2.01
P/FCF Ratio45.32
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue3.19
Enterprise Value/Gross Profit7.71
Enterprise Value/Ebitda18.64
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Margin & Operating Profit RecoveryGross margin expanded materially to ~41% (from ~30%) and operating income turned positive in 2025, reflecting durable manufacturing efficiencies and pricing power. Sustained margins reduce breakeven volume, improve operating leverage and make a path to lasting profitability more achievable if cost discipline and volumes persist.
Debt Elimination / Lower LeverageElimination of reported debt materially lowers financial risk and interest burden, increasing flexibility to fund yield/process improvements and commercial expansion. For a small animal‑health firm with prior losses this is a durable strength that eases refinancing pressure and preserves runway for execution if cash generation stabilizes.
Differentiated High‑Margin Product & Commercial BuildFirst Defense’s unique USDA‑approved non‑vaccine profile and higher neutralizing antibody levels create a structural competitive advantage and pricing power. Management’s targeted commercial hires and standardized selling approach support scalable uptake and margin retention, underpinning durable growth potential in a sizeable addressable market.
Bears Say
Weak & Unclear Cash GenerationReported operating/FCF at $0 in 2025 and historically inconsistent cash flows indicate limited internal funding capacity. This undermines the company’s ability to self‑fund capacity or commercial expansion, raises dependency on external financing, and is a persistent constraint on execution and strategic optionality over the medium term.
Ongoing Net Loss & Revenue VolatilityDespite operating improvement, the company reported a net loss in 2025 and revenue has swung materially across years. Persistent bottom‑line losses and top‑line unpredictability impair forecasting, complicate capacity utilization and weaken the durability of any margin improvements until revenue stability and consistent net profitability are demonstrated.
Impairments, Inventory Hits & Execution RiskNoncash impairments and inventory write‑downs reflect prior strategic shifts and inventory management challenges. The company’s growth plan hinges on realizing yield gains to reach 5–6M units without major capex; failure to deliver would constrain supply, margin realization and could prompt further write‑downs or costly corrective investments, a durable execution risk.
Immucell News
ICCC FAQ
What was Immucell Corp.’s price range in the past 12 months?
Immucell Corp. lowest stock price was $4.52 and its highest was $8.99 in the past 12 months.
What is Immucell Corp.’s market cap?
Immucell Corp.’s market cap is $78.98M.
When is Immucell Corp.’s upcoming earnings report date?
Immucell Corp.’s upcoming earnings report date is May 20, 2026 which is in 15 days.
How were Immucell Corp.’s earnings last quarter?
Immucell Corp. released its earnings results on Mar 04, 2026. The company reported -$0.315 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.315.
Is Immucell Corp. overvalued?
According to Wall Street analysts Immucell Corp.’s price is currently Overvalued.
Does Immucell Corp. pay dividends?
Immucell Corp. does not currently pay dividends.
What is Immucell Corp.’s EPS estimate?
Immucell Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immucell Corp. have?
Immucell Corp. has 9,046,799 shares outstanding.
What happened to Immucell Corp.’s price movement after its last earnings report?
Immucell Corp. reported an EPS of -$0.315 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.703%.
Which hedge fund is a major shareholder of Immucell Corp.?
Currently, no hedge funds are holding shares in ICCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immucell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
29.72%
12-Months-Change
Fundamentals
Return on Equity
-3.59%
Trailing 12-Months
Asset Growth
-5.69%
Trailing 12-Months
Company Description
Immucell Corp.
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
ICCC Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive operational and strategic turnaround: revenue grew 4.3% for the year, gross margins materially improved (41% vs 30% prior year), operating income swung to $1.6M from a loss, manufacturing capacity expanded and backorders were resolved, and management has doubled down on the high-margin First Defense franchise with commercial investments underway. Notable negatives include a $2.7M Re-Tain impairment, ~$650K of inventory write-downs, a remaining net loss of $1.0M, international timing-related weakness, and execution risk associated with planned capacity/yield improvements. Overall the positives (margin expansion, operating income turnaround, strategic focus and market opportunity) outweigh the negatives, though investors should monitor execution on capacity expansion and the impact of prior write-downs.View all ICCC earnings summariesTechnical Analysis
Medicinova
―
Adicet Bio
―
Werewolf Therapeutics
―
Telomir Pharmaceuticals, Inc.
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
4.00% Insiders
3.84% Mutual Funds
1.19% Other Institutional Investors
87.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---